Header Logo

Connection

JORGE CASTILLO to Middle Aged

Back to Details
This is a "connection" page, showing publications JORGE CASTILLO has written about Middle Aged.
JORGE CASTILLO
Connection Strength
2.364
Middle Aged
  1. Zanubrutinib for the treatment of Bing-Neel syndrome. Br J Haematol. 2025 Apr; 206(4):1136-1140.
    View in: PubMed
    Score: 0.060
  2. Follicular Lymphoma in Chile in the Adult Public Cancer Program: The Impact of Chemoimmunotherapy. Cancer Rep (Hoboken). 2024 Sep; 7(9):e2126.
    View in: PubMed
    Score: 0.058
  3. Plasmablastic lymphoma: 2024 update on diagnosis, risk stratification, and management. Am J Hematol. 2024 08; 99(8):1586-1594.
    View in: PubMed
    Score: 0.057
  4. Diffuse Large B-Cell Lymphoma in Chile: The Impact of Combined CHOP Plus Rituximab in the Public Health System. JCO Glob Oncol. 2022 11; 8:e2200165.
    View in: PubMed
    Score: 0.051
  5. Long-Term Follow-Up of Ibrutinib Monotherapy in Symptomatic, Previously Treated Patients With Waldenstr?m Macroglobulinemia. J Clin Oncol. 2021 02 20; 39(6):565-575.
    View in: PubMed
    Score: 0.044
  6. CXCR4 mutational status does not impact outcomes in patients with Waldenstr?m macroglobulinemia treated with proteasome inhibitors. Am J Hematol. 2020 04; 95(4):E95-E98.
    View in: PubMed
    Score: 0.042
  7. Deepening of response after completing rituximab-containing therapy in patients with Waldenstrom macroglobulinemia. Am J Hematol. 2020 04; 95(4):372-378.
    View in: PubMed
    Score: 0.042
  8. Outcomes of bendamustine- or cyclophosphamide-based first-line chemotherapy in older patients with indolent B-cell lymphoma. Am J Hematol. 2020 04; 95(4):354-361.
    View in: PubMed
    Score: 0.042
  9. CXCR4 mutation subtypes impact response and survival outcomes in patients with Waldenstr?m macroglobulinaemia treated with ibrutinib. Br J Haematol. 2019 11; 187(3):356-363.
    View in: PubMed
    Score: 0.040
  10. Long survival in patients with Waldenstr?m macroglobulinaemia diagnosed at a young age. Br J Haematol. 2019 05; 185(4):799-802.
    View in: PubMed
    Score: 0.039
  11. Ibrutinib Monotherapy in Symptomatic, Treatment-Na?ve Patients With Waldenstr?m Macroglobulinemia. J Clin Oncol. 2018 09 20; 36(27):2755-2761.
    View in: PubMed
    Score: 0.038
  12. Impact of ibrutinib dose intensity on patient outcomes in previously treated Waldenstr?m macroglobulinemia. Haematologica. 2018 10; 103(10):e466-e468.
    View in: PubMed
    Score: 0.037
  13. Low levels of von Willebrand markers associate with high serum IgM levels and improve with response to therapy, in patients with Waldenstr?m macroglobulinaemia. Br J Haematol. 2019 03; 184(6):1011-1014.
    View in: PubMed
    Score: 0.037
  14. Bortezomib plus EPOCH is effective as frontline treatment in patients with plasmablastic lymphoma. Br J Haematol. 2019 02; 184(4):679-682.
    View in: PubMed
    Score: 0.037
  15. The neutrophil-lymphocyte ratio is prognostic in patients with early stage aggressive peripheral T cell lymphoma. Br J Haematol. 2019 02; 184(4):650-653.
    View in: PubMed
    Score: 0.037
  16. Response and survival for primary therapy combination regimens and maintenance rituximab in Waldenstr?m macroglobulinaemia. Br J Haematol. 2018 04; 181(1):77-85.
    View in: PubMed
    Score: 0.037
  17. Ibrutinib discontinuation in Waldenstr?m macroglobulinemia: Etiologies, outcomes, and IgM rebound. Am J Hematol. 2018 08; 93(4):511-517.
    View in: PubMed
    Score: 0.037
  18. MYD88 wild-type Waldenstrom Macroglobulinaemia: differential diagnosis, risk of histological transformation, and?overall survival. Br J Haematol. 2018 02; 180(3):374-380.
    View in: PubMed
    Score: 0.036
  19. Late infections and secondary malignancies after bendamustine/rituximab or RCHOP/RCVP chemotherapy for B-cell lymphomas. Am J Hematol. 2018 01; 93(1):E1-E3.
    View in: PubMed
    Score: 0.036
  20. IgM myeloma: A multicenter retrospective study of 134 patients. Am J Hematol. 2017 Aug; 92(8):746-751.
    View in: PubMed
    Score: 0.035
  21. Serum IgM level as predictor of symptomatic hyperviscosity in patients with Waldenstr?m macroglobulinaemia. Br J Haematol. 2017 06; 177(5):717-725.
    View in: PubMed
    Score: 0.035
  22. Idelalisib in Waldenstr?m macroglobulinemia: high incidence of hepatotoxicity. Leuk Lymphoma. 2017 04; 58(4):1002-1004.
    View in: PubMed
    Score: 0.033
  23. Renal disease related to Waldenstr?m macroglobulinaemia: incidence, pathology and clinical outcomes. Br J Haematol. 2016 Nov; 175(4):623-630.
    View in: PubMed
    Score: 0.033
  24. Histological transformation to diffuse large B-cell lymphoma in patients with Waldenstr?m macroglobulinemia. Am J Hematol. 2016 10; 91(10):1032-5.
    View in: PubMed
    Score: 0.033
  25. Human immunodeficiency virus-associated lymphomas in the antiretroviral therapy era: Analysis of the National Cancer Data Base. Cancer. 2016 09 01; 122(17):2689-97.
    View in: PubMed
    Score: 0.033
  26. Transformation of a previously diagnosed diffuse large B-cell lymphoma to plasmablastic lymphoma. Am J Hematol. 2016 Aug; 91(8):E324.
    View in: PubMed
    Score: 0.032
  27. EBV-positive diffuse large B-cell lymphoma of the elderly: 2016 update on diagnosis, risk-stratification, and management. Am J Hematol. 2016 May; 91(5):529-37.
    View in: PubMed
    Score: 0.032
  28. Atrial fibrillation associated with ibrutinib in Waldenstr?m macroglobulinemia. Am J Hematol. 2016 06; 91(6):E312-3.
    View in: PubMed
    Score: 0.032
  29. Central nervous system involvement by multiple myeloma: A multi-institutional retrospective study of 172 patients in daily clinical practice. Am J Hematol. 2016 06; 91(6):575-80.
    View in: PubMed
    Score: 0.032
  30. Outcomes of HIV-associated Hodgkin lymphoma in the era of antiretroviral therapy. AIDS. 2016 Mar 13; 30(5):787-96.
    View in: PubMed
    Score: 0.032
  31. Cutaneous involvement in multiple myeloma: a multi-institutional retrospective study of 53 patients. Leuk Lymphoma. 2016 09; 57(9):2071-6.
    View in: PubMed
    Score: 0.032
  32. Central nervous system involvement by Waldenstr?m macroglobulinaemia (Bing-Neel syndrome): a multi-institutional retrospective study. Br J Haematol. 2016 Mar; 172(5):709-15.
    View in: PubMed
    Score: 0.032
  33. Relationship between obesity and clinical outcome in adults with acute myeloid leukemia: A pooled analysis from four CALGB (alliance) clinical trials. Am J Hematol. 2016 Feb; 91(2):199-204.
    View in: PubMed
    Score: 0.031
  34. Rituximab intolerance in patients with Waldenstr?m macroglobulinaemia. Br J Haematol. 2016 08; 174(4):645-8.
    View in: PubMed
    Score: 0.031
  35. Validation of clinical prognostic indices for diffuse large B-cell lymphoma in the National Cancer Data Base. Cancer Causes Control. 2015 Aug; 26(8):1163-72.
    View in: PubMed
    Score: 0.030
  36. Potential for improved survival with intensification of daunorubicin based induction chemotherapy in acute myeloid leukemia patients who do not receive transplant: A multicenter retrospective study. Leuk Res. 2015 Aug; 39(8):812-7.
    View in: PubMed
    Score: 0.030
  37. CD20-negative diffuse large B-cell lymphoma presenting with lactic acidosis. Am J Hematol. 2015 Mar; 90(3):E49-50.
    View in: PubMed
    Score: 0.030
  38. Treatment selection and outcomes in early-stage classical Hodgkin lymphoma: analysis of the National Cancer Data Base. J Clin Oncol. 2015 Feb 20; 33(6):625-33.
    View in: PubMed
    Score: 0.030
  39. Overall survival and competing risks of death in patients with?Waldenstr?m macroglobulinaemia: an analysis of the Surveillance, Epidemiology and End Results database. Br J Haematol. 2015 Apr; 169(1):81-9.
    View in: PubMed
    Score: 0.029
  40. Extranodal marginal zone lymphoma from ocular adnexae with subcutaneous involvement. Am J Dermatopathol. 2014 Nov; 36(11):e189-93.
    View in: PubMed
    Score: 0.029
  41. Prognostic factors for advanced-stage human immunodeficiency virus-associated classical Hodgkin lymphoma treated with doxorubicin, bleomycin, vinblastine, and dacarbazine plus combined antiretroviral therapy: a multi-institutional retrospective study. Cancer. 2015 Feb 01; 121(3):423-31.
    View in: PubMed
    Score: 0.029
  42. Carfilzomib, rituximab, and dexamethasone (CaRD) treatment offers a neuropathy-sparing approach for treating Waldenstr?m's macroglobulinemia. Blood. 2014 Jul 24; 124(4):503-10.
    View in: PubMed
    Score: 0.028
  43. The relation between cigarette smoking and risk of acute myeloid leukemia: an updated meta-analysis of epidemiological studies. Am J Hematol. 2014 Aug; 89(8):E125-32.
    View in: PubMed
    Score: 0.028
  44. Sites of extranodal involvement are prognostic in patients with diffuse large B-cell lymphoma in the rituximab era: an analysis of the Surveillance, Epidemiology and End Results database. Am J Hematol. 2014 Mar; 89(3):310-4.
    View in: PubMed
    Score: 0.028
  45. Population-based prognostic factors for survival in patients with Burkitt lymphoma: an analysis from the Surveillance, Epidemiology, and End Results database. Cancer. 2013 Oct 15; 119(20):3672-9.
    View in: PubMed
    Score: 0.027
  46. Similar outcomes in Asian and Western patients with diffuse large B-cell lymphoma treated with R-CHOP. Leuk Res. 2013 Apr; 37(4):386-91.
    View in: PubMed
    Score: 0.026
  47. Survival of patients with marginal zone lymphoma: analysis of the Surveillance, Epidemiology, and End Results database. Cancer. 2013 Feb 01; 119(3):629-38.
    View in: PubMed
    Score: 0.025
  48. Prognosis in primary effusion lymphoma is associated with the number of body cavities involved. Leuk Lymphoma. 2012 Dec; 53(12):2378-82.
    View in: PubMed
    Score: 0.025
  49. Human immunodeficiency virus-associated plasmablastic lymphoma: poor prognosis in the era of highly active antiretroviral therapy. Cancer. 2012 Nov 01; 118(21):5270-7.
    View in: PubMed
    Score: 0.024
  50. Peripheral T-cell lymphoma with a regulatory T-cell phenotype: report of a nodal and an extranodal case from Peru. Appl Immunohistochem Mol Morphol. 2012 Mar; 20(2):196-200.
    View in: PubMed
    Score: 0.024
  51. Rituximab in combination with chemotherapy versus chemotherapy alone in HIV-associated non-Hodgkin lymphoma: a pooled analysis of 15 prospective studies. Am J Hematol. 2012 Mar; 87(3):330-3.
    View in: PubMed
    Score: 0.024
  52. Risk factors associated with Clostridium difficile infection in adult oncology patients with a history of recent hospitalization for febrile neutropenia. Leuk Lymphoma. 2012 Aug; 53(8):1617-9.
    View in: PubMed
    Score: 0.024
  53. The Hans algorithm is not prognostic in patients with diffuse large B-cell lymphoma treated with R-CHOP. Leuk Res. 2012 Apr; 36(4):413-7.
    View in: PubMed
    Score: 0.024
  54. Prognostic factors in patients with HIV-associated peripheral T-cell lymphoma: a multicenter study. Am J Hematol. 2011 Mar; 86(3):256-61.
    View in: PubMed
    Score: 0.023
  55. Clinical and pathological differences between human immunodeficiency virus-positive and human immunodeficiency virus-negative patients with plasmablastic lymphoma. Leuk Lymphoma. 2010 Nov; 51(11):2047-53.
    View in: PubMed
    Score: 0.022
  56. Lymphopenia as a prognostic factor in patients with peripheral T-cell lymphoma, unspecified. Leuk Lymphoma. 2010 Oct; 51(10):1822-8.
    View in: PubMed
    Score: 0.022
  57. Extramedullary relapse of acute myeloid leukemia in a surgical wound. Leuk Lymphoma. 2011 Mar; 52(3):541-3.
    View in: PubMed
    Score: 0.022
  58. Prognostic factors in chemotherapy-treated patients with HIV-associated Plasmablastic lymphoma. Oncologist. 2010; 15(3):293-9.
    View in: PubMed
    Score: 0.021
  59. Depth of Response From Fixed-Duration Treatment Is Associated With Superior Survival in Waldenstrom Macroglobulinemia. Am J Hematol. 2025 Jun; 100(6):980-986.
    View in: PubMed
    Score: 0.015
  60. Simplified Risk Stratification Model for Patients With Waldenstr?m Macroglobulinemia. J Clin Oncol. 2024 Jul 20; 42(21):2527-2536.
    View in: PubMed
    Score: 0.014
  61. Lymphoplasmacytic lymphoma and multiple myeloma coexisting in the same patient: a case series and literature review. Leuk Lymphoma. 2024 Jul; 65(7):943-949.
    View in: PubMed
    Score: 0.014
  62. An international analysis evaluating frontline bendamustine with rituximab in extranodal marginal zone lymphoma. Blood Adv. 2022 04 12; 6(7):2035-2044.
    View in: PubMed
    Score: 0.012
  63. Venetoclax in Previously Treated Waldenstr?m Macroglobulinemia. J Clin Oncol. 2022 01 01; 40(1):63-71.
    View in: PubMed
    Score: 0.012
  64. Long-term follow-up of ibrutinib monotherapy in treatment-naive patients with Waldenstrom macroglobulinemia. Leukemia. 2022 02; 36(2):532-539.
    View in: PubMed
    Score: 0.012
  65. Real-World Data on Adult T-Cell Leukemia/Lymphoma in Latin America: A Study From the Grupo de Estudio Latinoamericano de Linfoproliferativos. JCO Glob Oncol. 2021 07; 7:1151-1166.
    View in: PubMed
    Score: 0.012
  66. Clinical, inflammatory and immunohistochemical features in a cohort of Peruvian patients with diffuse large B-cell lymphoma. Leuk Res. 2021 03; 102:106513.
    View in: PubMed
    Score: 0.011
  67. Partial response or better at six?months is prognostic of superior progression-free survival in Waldenstr?m macroglobulinaemia patients treated with ibrutinib. Br J Haematol. 2021 02; 192(3):542-550.
    View in: PubMed
    Score: 0.011
  68. A randomized phase 3 trial of zanubrutinib vs ibrutinib in symptomatic Waldenstr?m macroglobulinemia: the ASPEN study. Blood. 2020 10 29; 136(18):2038-2050.
    View in: PubMed
    Score: 0.011
  69. The BTK inhibitor ibrutinib may protect against pulmonary injury in COVID-19-infected patients. Blood. 2020 05 21; 135(21):1912-1915.
    View in: PubMed
    Score: 0.011
  70. A Multi-Institutional Validation of the Prognostic Value of the Neutrophil-to-Lymphocyte Ratio in Patients With Diffuse Large B-Cell Lymphoma: A Study From The Latin American Group of Lymphoproliferative Disorders (GELL). Clin Lymphoma Myeloma Leuk. 2020 10; 20(10):637-646.
    View in: PubMed
    Score: 0.011
  71. A multicenter retrospective study of 223 patients with t(14;16) in multiple myeloma. Am J Hematol. 2020 05; 95(5):503-509.
    View in: PubMed
    Score: 0.011
  72. Genomic evolution of ibrutinib-resistant clones in Waldenstr?m macroglobulinaemia. Br J Haematol. 2020 06; 189(6):1165-1170.
    View in: PubMed
    Score: 0.011
  73. Hematogenous extramedullary relapse in multiple myeloma - a multicenter retrospective study in 127 patients. Am J Hematol. 2019 10; 94(10):1132-1140.
    View in: PubMed
    Score: 0.010
  74. High Red Cell Distribution Width is an Adverse Predictive and Prognostic Factor in Patients With Diffuse Large B-Cell Lymphoma Treated With Chemoimmunotherapy. Clin Lymphoma Myeloma Leuk. 2019 09; 19(9):e551-e557.
    View in: PubMed
    Score: 0.010
  75. Progression Risk Stratification of Asymptomatic Waldenstr?m Macroglobulinemia. J Clin Oncol. 2019 06 01; 37(16):1403-1411.
    View in: PubMed
    Score: 0.010
  76. Ibrutinib for the treatment of Bing-Neel syndrome: a multicenter study. Blood. 2019 01 24; 133(4):299-305.
    View in: PubMed
    Score: 0.010
  77. Low risk of Pneumocystis jirovecii pneumonia and invasive aspergillosis in patients with Waldenstr?m macroglobulinaemia on ibrutinib. Br J Haematol. 2019 05; 185(4):788-790.
    View in: PubMed
    Score: 0.010
  78. Outcomes of secondary solid tumor malignancies among patients with myeloma: A population-based study. Cancer. 2019 02 15; 125(4):550-558.
    View in: PubMed
    Score: 0.010
  79. Profiling of circulating exosomal miRNAs in patients with Waldenstr?m Macroglobulinemia. PLoS One. 2018; 13(10):e0204589.
    View in: PubMed
    Score: 0.010
  80. TP53 mutations are associated with mutated MYD88 and CXCR4, and confer an adverse outcome in Waldenstr?m macroglobulinaemia. Br J Haematol. 2019 01; 184(2):242-245.
    View in: PubMed
    Score: 0.010
  81. Clinical characteristics and treatment outcomes in IgE multiple myeloma: A case-control study. Am J Hematol. 2018 09; 93(9):E238-E241.
    View in: PubMed
    Score: 0.009
  82. Secondary plasma cell leukemia: a multicenter retrospective study of 101 patients. Leuk Lymphoma. 2019 01; 60(1):118-123.
    View in: PubMed
    Score: 0.009
  83. The impact of the neutrophil:lymphocyte ratio in response and survival of patients with de novo diffuse large B-cell lymphoma. Leuk Res. 2018 04; 67:82-85.
    View in: PubMed
    Score: 0.009
  84. Prognostic indicators in primary plasma cell leukaemia: a multicentre retrospective study of 117 patients. Br J Haematol. 2018 03; 180(6):831-839.
    View in: PubMed
    Score: 0.009
  85. Survival of patients with CD20-negative variants of large B-cell lymphoma: an analysis of the National Cancer Data Base. Leuk Lymphoma. 2018 06; 59(6):1375-1383.
    View in: PubMed
    Score: 0.009
  86. Similar survival outcomes in patients with biclonal versus monoclonal myeloma: a multi-institutional matched case-control study. Ann Hematol. 2017 Oct; 96(10):1693-1698.
    View in: PubMed
    Score: 0.009
  87. Response and survival benefit with chemoimmunotherapy in Epstein-Barr virus-positive diffuse large B-cell lymphoma. Hematol Oncol. 2018 Feb; 36(1):93-97.
    View in: PubMed
    Score: 0.009
  88. Ibrutinib for patients with rituximab-refractory Waldenstr?m's macroglobulinaemia (iNNOVATE): an open-label substudy of an international, multicentre, phase 3 trial. Lancet Oncol. 2017 Feb; 18(2):241-250.
    View in: PubMed
    Score: 0.008
  89. Prospective, Multicenter Clinical Trial of Everolimus as Primary Therapy in Waldenstrom Macroglobulinemia (WMCTG 09-214). Clin Cancer Res. 2017 May 15; 23(10):2400-2404.
    View in: PubMed
    Score: 0.008
  90. Ibrutinib penetrates the blood brain barrier and shows efficacy in the therapy of Bing Neel syndrome. Br J Haematol. 2017 10; 179(2):339-341.
    View in: PubMed
    Score: 0.008
  91. Transcriptome sequencing reveals a profile that corresponds to genomic variants in Waldenstr?m macroglobulinemia. Blood. 2016 08 11; 128(6):827-38.
    View in: PubMed
    Score: 0.008
  92. To select or not to select? The role of B-cell selection in determining the MYD88 mutation status in Waldenstr?m Macroglobulinaemia. Br J Haematol. 2017 03; 176(5):822-824.
    View in: PubMed
    Score: 0.008
  93. Clonal architecture of CXCR4 WHIM-like mutations in Waldenstr?m Macroglobulinaemia. Br J Haematol. 2016 Mar; 172(5):735-44.
    View in: PubMed
    Score: 0.008
  94. The neutrophil-to-lymphocyte ratio is an independent prognostic factor in patients with peripheral T-cell lymphoma, unspecified. Leuk Lymphoma. 2016; 57(1):58-62.
    View in: PubMed
    Score: 0.008
  95. Survival outcomes of secondary cancers in patients with Waldenstr?m macroglobulinemia: An analysis of the SEER database. Am J Hematol. 2015 Aug; 90(8):696-701.
    View in: PubMed
    Score: 0.008
  96. Ibrutinib in previously treated Waldenstr?m's macroglobulinemia. N Engl J Med. 2015 Apr 09; 372(15):1430-40.
    View in: PubMed
    Score: 0.008
  97. Plasma fatty acid profile in multiple myeloma patients. Leuk Res. 2015 Apr; 39(4):400-5.
    View in: PubMed
    Score: 0.007
  98. Extramedullary Waldenstr?m macroglobulinemia. Am J Hematol. 2015 Feb; 90(2):100-4.
    View in: PubMed
    Score: 0.007
  99. Large B-cell lymphoma arising in cardiac myxoma or intracardiac fibrinous mass: a localized lymphoma usually associated with Epstein-Barr virus? Cardiovasc Pathol. 2015 Jan-Feb; 24(1):60-4.
    View in: PubMed
    Score: 0.007
  100. Impact of induction regimen and stem cell transplantation on outcomes in double-hit lymphoma: a multicenter retrospective analysis. Blood. 2014 Oct 09; 124(15):2354-61.
    View in: PubMed
    Score: 0.007
  101. Survival trends in Waldenstr?m macroglobulinemia: an analysis of the Surveillance, Epidemiology and End Results database. Blood. 2014 Jun 19; 123(25):3999-4000.
    View in: PubMed
    Score: 0.007
  102. Breast implant-associated anaplastic large-cell lymphoma: long-term follow-up of 60 patients. J Clin Oncol. 2014 Jan 10; 32(2):114-20.
    View in: PubMed
    Score: 0.007
  103. Follicular lymphoma with leukemic phase at diagnosis: a series of seven cases and review of the literature. Leuk Res. 2013 Sep; 37(9):1116-9.
    View in: PubMed
    Score: 0.007
  104. Extranodal marginal zone lymphoma of the cranial dura mater: report of three cases and systematic review of the literature. Leuk Lymphoma. 2013 Oct; 54(10):2306-9.
    View in: PubMed
    Score: 0.007
  105. EBV-positive diffuse large B-cell lymphoma of the elderly: a case series from Peru. Am J Hematol. 2011 Aug; 86(8):663-7.
    View in: PubMed
    Score: 0.006
  106. Different prognostic factors for survival in acute and lymphomatous adult T-cell leukemia/lymphoma. Leuk Res. 2011 Mar; 35(3):334-9.
    View in: PubMed
    Score: 0.005
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.